Abstract
Historically ablative treatment for hepatocellular cancer (HCC) has been regarded as inferior to transplantation and resection and has therefore been reserved for patients not suitable for surgical intervention in stage 0-A HCC according to the Barcelona Clinic Liver Cancer classification system. In the wake of surgical strategies challenging the current Barcelona Clinic Liver Cancer treatment guidelines and improvements in imaging, targeting and ablation technologies, ablation is likely to occupy a more central role in the management of patients with HCC, challenging its historically perceived inferiority to resection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
